本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2026/10/271 分钟阅读
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
本地自动翻译 · 来源原始语言
摘要
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review
来源原始语言: GlobeNewswire — Mergers and Acquisitions打开原始公告 →